| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi |
NCT00303316: Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants |
|
|
| Completed | 3 | 458 | RoW | DTaP-IPV//PRP~T combined vaccine, PENTAXIM™ | Sanofi | Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B | 04/07 | 09/07 | | |
NCT00315055 / 2011-004454-26: Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule |
|
|
| Completed | 3 | 310 | RoW | DTaP-IPV-HB-PRP~T vaccine, DTaP-IPV//PRP~T combined, PENTAXIM™, Hepatitis B vaccine, ENGERIX B® | Sanofi Pasteur, a Sanofi Company | Hepatitis B, Polio, Diphtheria, Pertussis | 07/07 | 02/08 | | |
NCT00401531 / 2011-004457-87: Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants |
|
|
| Completed | 3 | 412 | RoW | DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, Prevnar®, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines, Infanrix™-Hexa | Sanofi Pasteur, a Sanofi Company | Hepatitis B, Polio, Diphtheria, Pertussis, Haemophilus Influenzae Type b | 11/07 | 08/08 | | |
NCT00313911 / 2011-004431-31: Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. |
|
|
| Completed | 3 | 2133 | RoW | DTaP-IPV-HB-PRP~T, Tritanrix-HepB/Hib | Sanofi Pasteur, a Sanofi Company | Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b, Hepatitis B | 01/08 | 02/08 | | |
| Completed | 3 | 1189 | RoW | DTaP-IPV-HB-PRP~T vaccine, DTaP-HBV-IPV vaccine, INFANRIX®HEXA | Sanofi Pasteur, a Sanofi Company | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis | 04/08 | 07/08 | | |
NCT00362336 / 2011-004433-14: Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV |
|
|
| Completed | 3 | 622 | RoW | DTaP-IPV-HB-PRP~T, CombAct-HIB®, Engerix B® Pediatric | Sanofi Pasteur, a Sanofi Company | Hepatitis B, Polio, Diphtheria, Pertussis, Haemophilus Influenzae Type b | 05/08 | 08/09 | | |
NCT00619502 / 2011-004432-58: Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants |
|
|
| Completed | 3 | 254 | RoW | DTaP-IPV-HB-PRP~T vaccine | Sanofi Pasteur, a Sanofi Company | Diphtheria, Polio, Pertussis, Hepatitis B | 07/08 | 07/08 | | |
NCT00654901 / 2011-004456-19: Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ |
|
|
| Completed | 3 | 881 | RoW | DTaP-IPV-Hep B-PRP~T vaccine (Batch 1), DTaP-IPV-Hep B-PRP~T vaccine (Batch 2), DTaP-IPV-Hep B-PRP~T vaccine (Batch 3), Infanrix Hexa™ | Sanofi Pasteur, a Sanofi Company | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B Infection | 05/09 | 07/09 | | |
| Completed | 3 | 263 | RoW | DTaP IPV HB PRP~T vaccine, DTaP-HB-IPV and Haemophilus influenzae type b, Infanrix® Hexa | Sanofi Pasteur, a Sanofi Company | Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b, Hepatitis B | 05/09 | 11/09 | | |
NCT01444781 / 2011-004428-36: Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants |
|
|
| Completed | 3 | 1106 | RoW | DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide, DTaP-IPV-Hep B-PRP~T vaccine, Prevenar™, DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide, Infanrix hexa™, DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine, DTaP-IPV-Hep B-PRP~T combined vaccine | Sanofi Pasteur, a Sanofi Company | Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Poliomyelitis | 04/13 | 10/13 | | |
NCT01839175 / 2012-005547-24: Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination |
|
|
| Completed | 3 | 350 | Europe | Hexavalent vaccine, Diphtheria, tetanus, pertussis, hepatitis B,, poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed)., NeisVac-C, Meningococcal group C polysaccharide conjugate vaccine adsorbed, Prevenar 13, Pneumococcal conjugate vaccine (13-valent, adsorbed), RotaTeq, Human-bovine rotavirus reassortants (live) vaccine, Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, M-M-RVAXPRO, Measles, mumps and rubella vaccine (live) | Sanofi Pasteur, a Sanofi Company | Neisseria Meningitidis, Bacterial Infections, Virus Diseases | 07/14 | 02/15 | | |
NCT01948193 / 2016-002089-29: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth |
|
|
| Completed | 3 | 177 | RoW | Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine, Hexaxim™ | Sanofi Pasteur, a Sanofi Company | Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Poliomyelitis, Invasive Hib Infections | 12/14 | 06/15 | | |
NCT02094833 / 2016-002873-36: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants |
|
|
| Completed | 3 | 310 | RoW | DTaP-IPV-Hep B-PRP~T combined vaccine, DTaP-IPV//PRP~T and Hepatitis B vaccine, Pentaxim™, Euvax B® | Sanofi Pasteur, a Sanofi Company | Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b Infection, Poliomyelitis, Hepatitis B | 04/16 | 11/16 | | |
